The Fluxergy Analyzer is uniquely suited to offer a comprehensive menu of the most common POC tests on a single, cost-effective platform.
Irvine, CA, 7/26/2024 - Fluxergy announced that they will be presenting two posters at the Association of Diagnostic Laboratory Medicine (ADLM) meeting in Chicago, IL. From July 30th to August 1st, Fluxergy will present data on the platform and launch the company’s new business initiatives. Representatives of the company will be at booth #3446 for further discussion on this work and on potential collaboration opportunities with the company.
Posters:
These posters demonstrate the multimodal testing capability of the Fluxergy Analyzer and showcase initial feasibility data for select assay modalities.
Poster A-367: Development of a Multimodal Point-of-Care Diagnostic Platform to Perform Rapid, Accurate, and Cost-Effective Molecular, Immunochemistry, Clinical Chemistry, and Cytometry Tests
Access to point-of-care (POC) testing can make a significant impact on the quality of care. However, because POC diagnostic platforms available today are expensive and often only perform one testing modality, clinicians are unable to cost-effectively implement the POC tests they wish to perform in near-patient settings. Fluxergy is developing a multimodal POC diagnostic platform that consolidates diverse diagnostic modalities into a single, compact platform to minimize the cost of POC testing and standardize testing workflow for the most common clinical chemistry, cytometry, immunochemistry and molecular tests. This study describes feasibility studies performed to benchmark these assay modalities on the Fluxergy Analyzer.
Poster A-368: Feasibility of a Five-Minute Sample-to-Answer Basic Metabolic Panel for Point-of-Care Testing on the Fluxergy Analyzer
Adoption of point-of-care (POC) platforms has been limited by their high cost and limited menu (e.g., molecular only). Fluxergy has developed a cost-effective multimodal POC platform capable of performing the most common clinical chemistry, immunochemistry, hematology, molecular tests in CLIA-waived settings. This method comparison study describes the performance of the Fluxergy’s feasibility stage basic metabolic panel (BMP) with contrived samples compared to the Siemen’s epoc® Blood Analysis System and Abbott i-STAT® 1.
About Fluxergy
Fluxergy is revolutionizing point-of-care diagnostics with its innovative Fluxergy Platform, designed to make healthcare more accessible. Drawing on its expertise in the printed circuit board industry, Fluxergy's approach emphasizes affordability, flexibility, and scalability. These principles shape a unique design philosophy that sets Fluxergy apart in the diagnostics field, enabling quick development and large-scale production of superior diagnostic tests at significantly reduced costs. With its all-in-one platform designed for CLIA-waived settings, Fluxergy aims to provide a comprehensive range of common diagnostic tests on a single device, at prices below standard reimbursement rates, making point-of-care testing more viable for all healthcare providers.
The test systems described in these posters are currently under development and for investigational use only.
Fluxergy Works provides customers with an extremely intuitive user interface to set up and manage Fluxergy Analyzers, Fluxergy tests, and Fluxergy data. Fluxergy Works is designed to interface efficiently with common EMR, LIMS, and middleware.
- Compatible with PCs, tablets, and smartphones for data processing and local storage
- Cloud-based storage enabled with 256-bit encryption (HIPAA Compliant) for data privacy
- Over-the-air updates allows Fluxergy to respond to customer needs with new software updates
